Non-small cell lung cancer - historical

Back to Top
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main NSCLC page for current regimens.
Last updated on 2024-09-06:34 regimens on this page
52 variants on this page
 
=Neoadjuvant therapy=
==MIC==
MIC: Mitomycin, Ifosfamide, Cisplatin
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Rosell et al. 1994 	1989-1991 	Phase 3 (E-esc)	No preoperative therapy	Longer OS
Depierre et al. 2002	1991-1997 	Phase 3 (E-esc)	No preoperative therapy	Did not meet primary endpoint of OS
====Chemotherapy====
*Mitomycin (Mutamycin) 6 mg/m2 IV once on day 1
*Ifosfamide (Ifex) 3000 mg/m2 IV over 3 hours once on day 1
*Cisplatin (Platinol) 50 mg/m2 IV over 60 minutes once on day 1
====Supportive therapy====
*Mesna (Mesnex) 1000 mg/m2 IV over 3 hours once on day 1, admixed with ifosfamide
*Metoclopramide (Reglan) 3 mg/kg IV, given 30 minutes prior and 90 minutes after chemotherapy
*Dexamethasone (Decadron) 20 mg IV once, given 30 minutes prior to chemotherapy
21-day cycle for 3 cycles
====Subsequent treatment====
*Surgery
===References===
# Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A, Mate JL, Li S, Roig J, Olazábal A, Canela M, Ariza A, Skacel Z, Morera-Prat J, Abad A. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarié E, Gouva S, Paillot N, Bréchot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchâtre M, Coëtmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C; IFCT. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002 Jan 1;20(1):247-53. link to original article EuroPMC
=Adjuvant therapy=
==Radiation therapy==
RT: Radiation Therapy
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Keller et al. 2000 (ECOG E3590)	1991-1997 	Phase 3 (C)	EP & RT 	Did not meet endpoint of OS
====Preceding treatment====
*Complete surgical resection
====Radiotherapy====
*Radiation therapy, 180 cGy fractions x 28 fractions (total dose: 5040 cGy)
5-week course
===References===
# ECOG E3590: Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH; ECOG. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med. 2000 Oct 26;343(17):1217-22. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
=Induction therapy for locally advanced disease=
==MIC==
MIC: Mitomycin, Ifosfamide, Cisplatin
MIP: Mitomycin, Ifosfamide, Platinol (Cisplatin)
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Sculier et al. 1999	1989-1996 	Non-randomized part of phase 3 RCT	 	
Sculier et al. 2004	1996-2002 	Phase 3 (C) 	SuperMIP 	Did not meet primary endpoint of OS
====Chemotherapy====
*Mitomycin (Mutamycin) 6 mg/m2 IV bolus once on day 1, given first
*Ifosfamide (Ifex) 3000 mg/m2 IV over 3 hours once on day 1, given second
*Cisplatin (Platinol) 50 mg/m2 IV over 60 minutes once on day 1, given third, 3 hours after the end of ifosfamide infusion
====Supportive therapy====
*Mesna (Mesnex) 1000 mg/m2 IV over 3 hours once on day 1, given with ifosfamide, then 500 mg/m2 IV bolus at four and eight hours after ifosfamide
*Lorazepam (Ativan)
*Metoclopramide (Reglan)
*Dexamethasone (Decadron)
21- to 28-day cycle for 3 cycles
====Subsequent treatment====
*Sculier et al. 1999: MIP continuation x 3 versus RT consolidation
*Sculier et al. 2004: RT consolidation
===References===
# Sculier JP, Paesmans M, Lafitte JJ, Baumöhl J, Thiriaux J, van Cutsem O, Recloux P, Bureau G, Berchier MC, Zacharias C, Mommen P, Bosschaerts T, Berghmans T, van Houtte P, Ninane V, Klastersky J; European Lung Cancer Working Party. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. Ann Oncol. 1999 Mar;10(3):295-303. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Sculier JP, Lafitte JJ, Berghmans T, Van Houtte P, Lecomte J, Thiriaux J, Efremidis A, Koumakis G, Giner V, Richez M, Corhay JL, Wackenier P, Lothaire P, Paesmans M, Mommen P, Ninane V; European Lung Cancer Working Party. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol. 2004 Mar;15(3):399-409. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==PEV==
PEV: Platinol (Cisplatin), Etoposide, Vinblastine
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Kim et al. 2002	1988-1992 	Phase 3 (E-esc)	No induction chemotherapy	Might have longer OS
====Chemotherapy====
*Cisplatin (Platinol) 20 mg/m2 IV once per day on days 1 to 5
*Etoposide (Vepesid) 100 mg/m2 IV once per day on days 2 to 4
*Vinblastine (Velban) 6 mg/m2 IV once on day 1
21-day cycle for 3 cycles
====Subsequent treatment====
*RT consolidation
===References===
# Kim TY, Yang SH, Lee SH, Park YS, Im YH, Kang WK, Ha SH, Park CI, Heo DS, Bang YJ, Kim NK. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol. 2002 Jun;25(3):238-43. link to original article EuroPMC
=Definitive therapy for locally advanced disease=
==MVP & RT==
MVP & RT: Mitomycin, Vindesine, Platinol (Cisplatin), Radiation Therapy
===Regimen variant #1===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Furuse et al. 1999 (JCOG9202)	1992-1994 	Phase 3 (E-switch-ic)	MVP, then RT	Seems to have longer OS
====Chemotherapy====
*Mitomycin (Mutamycin) 8 mg/m2 IV once per day on days 1 & 29
*Vindesine (Eldisine) 3 mg/m2 IV once per day on days 1, 8, 29, 36
*Cisplatin (Platinol) 80 mg/m2 IV once per day on days 1 & 29
====Radiotherapy====
*Concurrent External beam radiotherapy 5600 cGy in 28 fractions, given on days 1 to 5, 8 to 12, 15 to 19, 29 to 33, 36 to 40, 43 to 46
46-day course
===Regimen variant #2===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Yamamoto et al. 2010 (WJTOG0105)	2001-2005 	Phase 3 (C)	1. CP & RT 	Inconclusive whether non-inferior OS (primary endpoint)Median OS: 20.5 vs 22 mo(HR not reported)
Yamamoto et al. 2010 (WJTOG0105)	2001-2005 	Phase 3 (C)	2. Carboplatin, Irinotecan, RT	Inconclusive whether non-inferior OS (primary endpoint)Median OS: 20.5 vs 19.8 mo(HR not reported)
====Chemotherapy====
*Mitomycin (Mutamycin) 8 mg/m2 IV once on day 1
*Vindesine (Eldisine) 3 mg/m2 IV once per day on days 1 & 8
*Cisplatin (Platinol) 80 mg/m2 IV once on day 1
====Radiotherapy====
*Concurrent External beam radiotherapy as follows (total dose 6000 cGy):
**Cycles 1 & 3: 200 cGy per fraction x 15 fractions, given on days 2 to 6, 9 to 13, 16 to 20
28-day cycle for 4 cycles
===References===
# JCOG9202: Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#WJTOG0105: Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010 Aug 10;28(23):3739-45. Epub 2010 Jul 12. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00144053
##Update: Zenke Y, Tsuboi M, Chiba Y, Tsujino K, Satouchi M, Sawa K, Shimizu J, Daga H, Fujimoto D, Mori M, Aoki T, Sawa T, Omori S, Saka H, Iwamoto Y, Okuno M, Hirashima T, Kashiwabara K, Tachihara M, Yamamoto N, Nakagawa K. Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non-Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Jun 1;7(6):904-909. link to original article link to PMC article EuroPMC
=Maintenance after definitive therapy for inoperable disease=
==BCG vaccine monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Pines 1976	1970-1973 	Randomized (E-esc)	Observation	Seems to have longer OS
====Preceding treatment====
*RT consolidation
====Immunotherapy====
*BCG vaccine
===References===
# Pines A. A 5-year controlled study of BCG and radiotherapy inoperable lung cancer. Lancet. 1976 Feb 21;1(7956):380-1. link to original article EuroPMC
=Advanced or metastatic disease, first-line=
==CAMP==
CAMP: Cyclophosphamide, Adriamycin (Doxorubicin), Methotrexate, Procarbazine
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Bitran et al. 1978 	1975-1977 	Non-randomized 	 	
Ruckdeschel et al. 1986 (ECOG E1581)	1981-1983 	Randomized (E-esc)	1. MVP2. EC 3. VC	Did not meet primary endpoint
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 300 mg/m2 IV push once per day on days 1 & 8
*Doxorubicin (Adriamycin) 20 mg/m2 IV push once per day on days 1 & 8 (maximum cumulative dose of 450 mg/m2)
*Methotrexate (MTX) 15 mg/m2 IV push once per day on days 1 & 8
*Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 10 or days 2 to 11
28-day cycles
===References===
# Bitran JD, Desser RK, DeMeester T, Golomb HM. Metastatic non-oat-cell bronchogenic carcinoma: therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA. 1978 Dec 15;240(25):2743-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Carboplatin & Cisplatin==
CC: Cisplatin & Carboplatin
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Sculier et al. 1998	1990-1995 	Phase 3 (C)	CCI 	Lower ORR
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
====Chemotherapy====
*Carboplatin (Paraplatin) 200 mg/m2 IV over 30 minutes once on day 1
*Cisplatin (Platinol) 30 mg/m2 IV over 15 minutes once per day on days 2 & 3
21- to 28-day cycles
===References===
# Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Efremidis A, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V, Klastersky J; European Lung Cancer Working Party. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1998 Apr;16(4):1388-96. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Carboplatin & Paclitaxel (CP) & Cetuximab==
CP & Cetuximab: Carboplatin, Paclitaxel, Cetuximab
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Lynch et al. 2010 (BMS099)	2005-01 to 2006-11 	Phase 3 (E-esc)	1a. CP1b. DCb	Did not meet primary endpoint of PFSMedian PFS: 4.4 vs 4.24 mo(HR 0.90, 95% CI 0.76-1.07)
====Chemotherapy====
*Carboplatin (Paraplatin) as follows:
**Cycles 1 to 6: AUC 6 IV over 30 minutes once on day 1
*Paclitaxel (Taxol) as follows:
**Cycles 1 to 6: 225 mg/m2 IV over 3 hours once on day 1
====Targeted therapy====
*Cetuximab (Erbitux) as follows:
**Cycle 1: 400 mg/m2 IV over 2 hours once on day 1, then 250 mg/m2 IV over 60 minutes once per day on days 8 & 15
**Cycle 2 onwards: 250 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
21-day cycles
===References===
#Thienelt CD, Bunn PA Jr, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 1;23(34):8786-93. Epub 2005 Oct 24. link to original article EuroPMC
#BMS099: Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, Pautret V, Weber MR, Woytowitz D. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010 Feb 20;28(6):911-7. Epub 2010 Jan 25. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00112294
==CCI==
CCI: Cisplatin, Carboplatin, Ifosfamide
===Regimen variant #1===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Sculier et al. 2002	1998-2000 	Phase 3 (C)	1. CCG2. IG	Did not meet primary endpoint of OS
====Chemotherapy====
*Carboplatin (Paraplatin) AUC 3 IV over 30 minutes once on day 1, given second
*Cisplatin (Platinol) 60 mg/m2 IV over 60 minutes once on day 1, given third
*Ifosfamide (Ifex) 4500 mg/m2 IV over 3 hours once on day 1, given first
====Supportive therapy====
*Mesna (Mesnex)
28-day cycles
===Regimen variant #2===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Sculier et al. 1998	1990-1995 	Phase 3 (E-esc)	CC 	Higher ORR
====Chemotherapy====
*Carboplatin (Paraplatin) 200 mg/m2 IV over 30 minutes once on day 1, given first
*Cisplatin (Platinol) 30 mg/m2 IV over 15 minutes once per day on days 2 & 3, given first
*Ifosfamide (Ifex) 1500 mg/m2 IV over 3 hours once per day on days 1 to 3, given second
====Supportive therapy====
*Mesna (Mesnex) 300 mg/m2 IV once on day 1, given prior to first dose of ifosfamide, then 300 mg/m2 IV every 4 hours for 72 hours
21- to 28-day cycles
===References===
# Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Efremidis A, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V, Klastersky J; European Lung Cancer Working Party. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1998 Apr;16(4):1388-96. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, Efremidis A, Alexopoulos CG, Recloux P, Ninane V, Mommen P, Paesmans M, Klastersky J; European Lung Cancer Working Party. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol. 2002 Jun;13(6):874-82. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==CISCA==
CISCA: CISplatin, Cyclophosphamide, Adriamycin (Doxorubicin)
CAP: Cyclophosphamide, Adriamycin (Doxorubicin), Platinol (Cisplatin)
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Robert et al. 1984 	1978-1981 	Phase 3 (C)	1. Cyclophosphamide & Doxorubicin (AC)2. CAMF	Did not meet endpoint of OS
Miller et al. 1986 (SWOG S8012)	1980-1983 	Phase 3 (C)	1. FOMi2. FOMi/CAP 	Seems to have shorter OS
====Chemotherapy====
*Cyclophosphamide (Cytoxan) 400 mg/m2 IV once on day 1
*Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1
*Cisplatin (Platinol) 40 mg/m2 IV once on day 1
21-day cycles
===References===
# Robert F, Omura GA, Birch R, Krauss S, Oldham R; SECG. Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: a Southeastern Cancer Study Group trial. J Clin Oncol. 1984 May;2(5):391-5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# SWOG S8012: Miller TP, Chen TT, Coltman CA Jr, O'Bryan RM, Vance RB, Weiss GB, Fletcher WS, Stephens RL, Livingston RB. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung: a Southwest Oncology Group Study. J Clin Oncol. 1986 Apr;4(4):502-8. link to original article EuroPMC
==Cisplatin monotherapy==
===Regimen variant #1, 75 q3wk x 8===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
von Pawel et al. 2000 (CATAPULT I)	Not reported 	Phase 3 (C)	Cisplatin & Tirapazamine	Shorter OS
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
====Chemotherapy====
*Cisplatin (Platinol) 75 mg/m2 IV once on day 1
21-day cycle for up to 8 cycles
===Regimen variant #2, 100 q3wk===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Gatzemeier et al. 2000	1995-01 to 1996-04 	Phase 3 (C)	Cisplatin & Paclitaxel	Seems to have shorter TTP
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
====Chemotherapy====
*Cisplatin (Platinol) 100 mg/m2 IV over 30 minutes once on day 1
21-day cycle for up to 6 cycles
===Regimen variant #3, 100 q4wk===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Gandara et al. 1993 	1988-1990 	Phase 3 (C)	1. Cisplatin; high-dose2. HDCP-M	Did not meet endpoint of OS
Wozniak et al. 1998 (SWOG S9308)	1993-1995 	Phase 3 (C)	CVb 	Shorter OS
Sandler et al. 2000 	1995-1997 	Phase 3 (C)	GC 	Shorter OS
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
====Chemotherapy====
*Cisplatin (Platinol) 100 mg/m2 IV over 30 to 120 minutes once on day 1
28-day cycle for 6 cycles (Sandler et al. 2000) or indefinitely
===References===
# Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP; SWOG. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993 May;11(5):873-8. link to original article EuroPMC
#SWOG S9308: Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB; SWOG. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul;16(7):2459-65. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000 Jan;18(1):122-30. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# CATAPULT I: von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group: cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol. 2000 Mar;18(6):1351-9. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Cisplatin & Pemetrexed==
Pem-Cis: Pemetrexed & Cisplatin
Cis-Pem: Cisplatin & Pemetrexed
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Scagliotti et al. 2008 (JMDB)	2004-07 to 2005-12 	Phase 3 (E-RT-switch-ic)	Cisplatin & Gemcitabine	Seems to have non-inferior OS (primary endpoint)Median OS: 10.3 vs 10.3 mo(HR 0.94, 95% CI 0.84-1.05)
Note: although this regimen is still current for nonsquamous NSCLC, the JMDB trial was unselected by histology.
====Chemotherapy====
*Cisplatin (Platinol) 75 mg/m2 IV once on day 1
*Pemetrexed (Alimta) 500 mg/m2 IV once on day 1
====Supportive therapy====
*Cyanocobalamin (Vitamin B12) 1000 mcg IM every 9 weeks, first dose 1 to 2 weeks prior to pemetrexed
*Folic acid (Folate) 350 mcg to 1 mg PO once per day
*Dexamethasone (Decadron) 4 mg PO twice to day on days -1 to 2
21-day cycle for 6 cycles
===References===
# JMDB: Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543-51. Epub 2008 May 27. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Cisplatin & Vinblastine==
VP: Vinblastine & Platinol (Cisplatin)
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Kosty et al. 1994 (CALGB 8931)	1989-1991 	Phase 3 (C)	VP & Hydrazine	Did not meet primary endpoint of OS
====Chemotherapy====
*Cisplatin (Platinol) 100 mg/m2 IV once on day 1
*Vinblastine (Velban) as follows:
**Cycle 1: 5 mg/m2 IV once per day on days 1, 8, 15, 22
**Cycle 2 onwards: 5 mg/m2 IV once per day on days 1 & 15
28-day cycles
===References===
# CALGB 8931: Kosty MP, Fleishman SB, Herndon JE 2nd, Coughlin K, Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green MR; CALGB. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol. 1994 Jun;12(6):1113-20. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
==Cisplatin & Vindesine==
VP: Vindesine & Platinol (Cisplatin)
VdsC: Vindesine & Cisplatin
===Regimen variant #1, 80/3===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Masutani et al. 1999	1987-1992 	Phase 3 (C) 	1. PVI2. PVM 	Did not meet endpoint of OS
Negoro et al. 2003 	1995-1998 	Phase 3 (C) 	1. Cisplatin & Irinotecan	Did not meet primary endpoint of OS
Negoro et al. 2003 	1995-1998 	Phase 3 (C) 	2. Irinotecan 	Non-inferior OS (primary endpoint)
Kubota et al. 2004 	1998-2000 	Phase 3 (E-switch-ic)	Cisplatin & Docetaxel 	Seems to have shorter OS (primary endpoint)
====Chemotherapy====
*Cisplatin (Platinol) 80 mg/m2 IV over 1 to 2 hours once on day 1
*Vindesine (Eldisine) 3 mg/m2 IV bolus once per day on days 1, 8, 15
28-day cycle for 2 or more cycles
===Regimen variant #2, 100/3; split-dose cisplatin===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Kodani et al. 2002	1987-1992 	Phase 3 (C)	PVI 	Did not meet endpoint of ORR
====Chemotherapy====
*Cisplatin (Platinol) 20 mg/m2 IV once per day on days 1 to 5
*Vindesine (Eldisine) 3 mg/m2 IV once per day on days 1 & 8
28-day cycle for 5 cycles
===Regimen variant #3, 100/3; capped vindesine===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Vansteenkiste et al. 2001	1996-1999 	Phase 3 (C)	Gemcitabine	Seems to have lower clinical benefit
====Chemotherapy====
*Cisplatin (Platinol) 100 mg/m2 IV over 1 to 4 hours once on day 1
*Vindesine (Eldisine) 3 mg/m2 (maximum dose of 5 mg) IV once per day on days 1 & 15
28-day cycles
===Regimen variant #4, 120/3, 4-week induction===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Rapp et al. 1988	1983-1986 	Phase 3 (E-esc)	Best supportive care	Longer OS
====Chemotherapy====
*Cisplatin (Platinol) as follows:
**Cycle 1: 120 mg/m2 IV once per day on days 1 & 29
**Cycle 2 onwards: 120 mg/m2 IV once on day 1
*Vindesine (Eldisine) as follows:
**Cycle 1: 3 mg/m2 IV once per day on days 1, 8, 15, 22, 36, 50
**Cycle 2 onwards: 3 mg/m2 IV once per day on days 1, 15, 29
9-week course, then 42-day cycles
===Regimen variant #5, 120/3, 5-week induction===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Ruckdeschel et al. 1986 (ECOG E1581)	1981-1983 	Phase 3 (E-de-esc)	1. CAMP2. EC 3. MVP	Did not meet primary endpoint
====Chemotherapy====
*Cisplatin (Platinol) as follows:
**Cycle 1: 120 mg/m2 IV once per day on days 1 & 29
**Cycle 2 onwards: 120 mg/m2 IV once on day 1
*Vindesine (Eldisine) as follows:
**Cycle 1: 3 mg/m2 IV once per day on days 1, 8, 15, 22, 29, 43, 57
**Cycle 2 onwards: 3 mg/m2 IV once per day on days 8, 22, 36
10-week course, then 42-day cycles
===Regimen variant #6, 120/3, 6-week induction===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Le Chevalier et al. 1994	1989-1991 	Phase 3 (C)	1. CVb 	Seems to have shorter OS
Le Chevalier et al. 1994	1989-1991 	Phase 3 (C)	2. Vinorelbine	Not reported
====Chemotherapy====
*Cisplatin (Platinol) as follows:
**Cycle 1: 120 mg/m2 IV once per day on days 1 & 29
**Cycle 2 onwards: 120 mg/m2 IV once on day 29
*Vindesine (Eldisine) as follows:
**Cycle 1: 3 mg/m2 IV once per day on days 1, 8, 15, 22, 29, 36
**Cycle 2 onwards: 3 mg/m2 IV once per day on days 1, 15, 29
42-day cycles
===References===
# ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633-41. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffle P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360-7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Masutani M, Akusawa H, Kadota A, Ohchi Y, Takahashi N, Tanigawa S, Koya Y, Horie T. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology. 1996 Mar;1(1):49-54. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL; Leuven Lung Cancer Group. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol. 2001 Sep;12(9):1221-30. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y, Moritaka T, Hiraki S, Harada M, Tanimoto M. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer. 2002 Jun;36(3):313-9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M; CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003 Feb 10;88(3):335-41. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
# Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Yokota S, Yoneda S, Matsui K, Kudo S, Shibuya M, Isobe T, Segawa Y, Nishiwaki Y, Ohashi Y, Niitani H; Japanese Taxotere Lung Cancer Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol. 2004 Jan 15;22(2):254-61. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Docetaxel monotherapy==
===Regimen variant #1, 75 mg/m2===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Moro-Sibilot et al. 2015 (IFCT-0702)	2007-11 to 2012-08 	Phase 3 (C)	1a. DCb1b. DC	Did not meet primary endpoint of PFSMedian PFS: 5.6 vs 8 mo(HR 1.41, 95% CI 0.91-2.22)
====Chemotherapy====
*Docetaxel (Taxotere) 75 mg/m2 IV once on day 1
21-day cycle for 6 cycles
===Regimen variant #2, 100 mg/m2===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Roszkowski et al. 2000 	1995 to not reported	Phase 3 (E-esc)	Best supportive care	Seems to have longer OS
Georgoulias et al. 2007	2002-2004 	Phase 3 (C) 	DG 	Seems to have shorter OS
====Chemotherapy====
*Docetaxel (Taxotere) 100 mg/m2 IV over 60 minutes once on day 1
21-day cycles
===References===
# Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R, Berille J. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000 Mar;27(3):145-57. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#IFCT-0702: Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavolé A, Mazières J, Toffart AC, Langlais A, Morin F, Zalcman G. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). Lung Cancer. 2015 Aug;89(2):139-45. Epub 2015 May 27. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00535275
==Docetaxel & Gemcitabine==
DG: Docetaxel & Gemcitabine
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Georgoulias et al. 2007	2002-2004 	Phase 3 (E-esc)	Docetaxel 	Seems to have longer OS (primary endpoint)Median OS: 9.4 vs 8.3 mo
Note: while this was the superior arm of a phase 3 RCT, the comparator (single-agent docetaxel) is not usually used in the first-line treatment and this regimen is not currently recommended by ESMO guidelines.
====Chemotherapy====
*Docetaxel (Taxotere) 1100 mg/m2 IV once per day on days 1 & 8
*Gemcitabine (Gemzar) 75 mg/m2 IV once on day 8
21-day cycles
===References===
# Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
==FULV==
FULV: 5-FU & LeucoVorin
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Crawford et al. 1996	1990-1992 	Randomized (C)	Vinorelbine	Seems to have shorter OS
Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
====Chemotherapy====
*Fluorouracil (5-FU) 425 mg/m2 IV once per day on days 1 to 5, given second
*Leucovorin (Folinic acid) 20 mg/m2 IV bolus once per day on days 1 to 5, given first
28-day cycles
===References===
# Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 1996 Oct;14(10):2774-84. Erratum in: J Clin Oncol 1996 Dec;14(12):3175. Spiridonitis CH [corrected to Spiridonidis CH]. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Gemcitabine monotherapy==
===Regimen variant #1, 1000 mg/m2, 3 out of 4 weeks===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Vansteenkiste et al. 2001	1996-1999 	Phase 3 (E-de-esc)	Cisplatin & Vindesine	Seems to have better clinical benefit
Note: this regimen is considered current in elderly patients or those with poor PS; these trials were unselected by these parameters.
====Chemotherapy====
*Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
===Regimen variant #2, 1250 mg/m2, 2 out of 3 weeks===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Sederholm et al. 2005	1998-2001 	Phase 3 (E-de-esc)	Carboplatin & Gemcitabine	Seems to have shorter OS
Note: this regimen is considered current in elderly patients or those with poor PS; these trials were unselected by these parameters.
====Chemotherapy====
*Gemcitabine (Gemzar) 1250 mg/m2 IV once per day on days 1 & 8
21-day cycles
===References===
# Vansteenkiste JF, Vandebroek JE, Nackaerts KL, Weynants P, Valcke YJ, Verresen DA, Devogelaere RC, Marien SA, Humblet YP, Dams NL; Leuven Lung Cancer Group. Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol. 2001 Sep;12(9):1221-30. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Sederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==GIP==
GIP: Gemcitabine, Ifosfamide, Platinol (Cisplatin)
===Regimen===
Study 	Dates of enrollment	Evidence
Sculier et al. 2007	2000-2004 	Non-randomized part of phase 3 RCT
====Chemotherapy====
*Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on days 1 & 8
*Ifosfamide (Ifex) 3000 mg/m2 IV once on day 1
*Cisplatin (Platinol) 50 mg/m2 IV once on day 1
21-day cycle for 3 cycles 
===References===
# Sculier JP, Lafitte JJ, Lecomte J, Alexopoulos CG, Van Cutsem O, Giner V, Efremidis A, Berchier MC, Collon T, Meert AP, Scherpereel A, Ninane V, Paesmans M, Berghmans T; European Lung Cancer Working Party. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Ann Oncol. 2007 Jun;18(6):1037-42. Epub 2007 Apr 2. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Ifosfamide monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Fossella et al. 2000 (TAX 320)	1995-1998 	Phase 3 (C)	1. Docetaxel; 100 mg/m2	Did not meet primary endpoint of OS
Fossella et al. 2000 (TAX 320)	1995-1998 	Phase 3 (C)	2. Docetaxel; 75 mg/m2 	Did not meet primary endpoint of OS
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
====Chemotherapy====
*Ifosfamide (Ifex) 2000 mg/m2 IV once per day on days 1 to 3
====Supportive therapy====
*Mesna (Mesnex)
21-day cycles
===References===
#TAX 320: Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L; TAX 320 Non-Small Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000 Jun;18(12):2354-62. Erratum in: J Clin Oncol. 2004 Jan 1;22(1):209. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
==Ifosfamide & Gemcitabine==
IG: Ifosfamide & Gemcitabine
===Regimen variant #1, 3000/1000===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Berghmans et al. 2013 (ELCWP-01041)	2003-2009 	Phase 3 (C)	1. GIP2. DP	Did not meet primary endpoint of OS
Note: to our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm. Cycle length was not explicitly declared in the manuscript and was inferred from other variants.
====Chemotherapy====
*Ifosfamide (Ifex) 3000 mg/m2 IV once on day 1
*Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on day 1, 8, 15
28-day cycles
===Regimen variant #2, 4500/1000===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Sculier et al. 2002	1998-2000 	Phase 3 (E-esc)	1. CCI2. CCG	Did not meet primary endpoint of OS
Note: This was an experimental arm that did not meet its primary endpoint; included here because it was likely used to establish this regimen as a standard comparator.
====Chemotherapy====
*Ifosfamide (Ifex) 4500 mg/m2 IV once on day 1
*Gemcitabine (Gemzar) 1000 mg/m2 IV once per day on day 1, 8, 15
28-day cycles
===References===
# Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, Efremidis A, Alexopoulos CG, Recloux P, Ninane V, Mommen P, Paesmans M, Klastersky J; European Lung Cancer Working Party. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol. 2002 Jun;13(6):874-82. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# ELCWP-01041: Berghmans T, Lafitte JJ, Scherpereel A, Paesmans M, Lecomte J, Marco VG, Meert AP, Leclercq N, Sculier JP; European Lung Cancer Working Party. An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC. Anticancer Res. 2013 Dec;33(12):5477-82. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00622349
==Irinotecan monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Negoro et al. 2003	1995-1998 	Phase 3 (E-de-esc)	1. Cisplatin & Vindesine	Non-inferior OS (primary endpoint)Median OS: 46 vs 45.6 weeks(HR 0.83, 95% CI 0.64-1.09)
Negoro et al. 2003	1995-1998 	Phase 3 (E-de-esc)	2. IC 	Not reported
====Chemotherapy====
*Irinotecan (Camptosar) 100 mg/m2 IV once per day on days 1, 8, 15
28-day cycles
===References===
#Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M; CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer. 2003 Feb 10;88(3):335-41. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
==MACC==
MACC: Methotrexate, Adriamycin (Doxorubicin), Cyclophosphamide, CCNU (Lomustine)
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Chahinian et al. 1977	Not reported 	Non-randomized 	 	
Cormier et al. 1982 	Not reported 	Phase 3 (E-esc)	Placebo 	Longer OS
====Chemotherapy====
*Methotrexate (MTX) 40 mg/m2 IV once on day 1
*Doxorubicin (Adriamycin) 40 mg/m2 IV once on day 1
*Cyclophosphamide (Cytoxan) 400 mg/m2 IV once on day 1
*Lomustine (CCNU) 30 mg/m2 PO once on day 1, taken on an empty stomach
21-day cycles
===References===
# Chahinian PA, Arnold DJ, Cohen JM, Purpora DP, Jaffrey IS, Teirstein AS, Kirschner PA, Holland JF. Chemotherapy for bronchogenic carcinoma: methotrexate, doxorubicin, cyclophosphamide, and lomustine. JAMA. 1977 May 30;237(22):2392-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Cormier Y, Bergeron D, La Forge J, Lavandier M, Fournier M, Chenard J, Desmeules M. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982 Sep 1;50(5):845-9. link to original article EuroPMC
==MIC==
MIC: Mitomycin, Ifosfamide, Cisplatin
MIP: Mitomycin, Ifosfamide, Platinol (Cisplatin)
===Regimen variant #1===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Danson et al. 2003	1997-2001 	Phase 3 (C)	GC 	Did not meet primary endpoint of OS
Rudd et al. 2005 	1999-2001 	Phase 3 (C)	GC 	Shorter OS (primary endpoint)Median OS: 7.6 vs 10 mo(HR 1.32, 95% CI 1.08-1.64)
====Chemotherapy====
*Mitomycin (Mutamycin) 6 mg/m2 IV bolus once on day 1
*Ifosfamide (Ifex) 3000 mg/m2 IV over 3 hours once on day 1
*Cisplatin (Platinol) 50 mg/m2 IV over 60 minutes once on day 1
====Supportive therapy====
*Mesna (Mesnex) 1500 mg/m2 IV over 4 hours once on day 1, given after cisplatin
21-day cycle for 4 cycles
===Regimen variant #2===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Cullen et al. 1999 (MIC2) 	1988-1996 	Phase 3 (E-esc)	Best supportive care	Seems to have longer OS
Sculier et al. 2000 	1995-1998 	Phase 3 (C) 	CarboMIP 	Did not meet primary endpoint of OS
Booton et al. 2006 (BTOG1)	2001-06 to 2002-11 	Phase 3 (C) 	DCb 	Did not meet primary endpoint of OS12OS12: 35% vs 39%
====Chemotherapy====
*Mitomycin (Mutamycin) 6 mg/m2 IV bolus once on day 1, given first
*Ifosfamide (Ifex) 3000 mg/m2 IV over 3 hours once on day 1, given second
*Cisplatin (Platinol) 60 mg/m2 IV over 60 minutes once on day 1, given third, 3 hours after end of ifosfamide
====Supportive therapy====
*Mesna (Mesnex) 1000 mg/m2 IV over 3 hours once on day 1, given with ifosfamide, then 500 mg/m2 IV bolus at 4 hours and 8 hours after ifosfamide
21-day cycles
===Regimen variant #3, higher-dose cisplatin===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Crinò et al. 1999	1995-1997 	Phase 3 (C)	Cisplatin & Gemcitabine	Seems to have lower ORR
====Chemotherapy====
*Mitomycin (Mutamycin) 6 mg/m2 IV once on day 1
*Ifosfamide (Ifex) 3000 mg/m2 IV once on day 1
*Cisplatin (Platinol) 100 mg/m2 IV once on day 2
====Supportive therapy====
*Mesna (Mesnex) 600 mg/m2 IV once on day 1, given with ifosfamide, then 600 mg/m2 IV at 4 hours and 8 hours after ifosfamide
28-day cycles
===References===
# MIC2: Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999 Oct;17(10):3188-94. link to original article EuroPMC
# Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999 Nov;17(11):3522-30. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J, Schmerber J, Koumakis G, Florin MC, Zacharias C, Berghmans T, Mommen P, Ninane V, Klastersky J. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer. 2000 Nov;83(9):1128-35. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
# Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
#Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JA, Hatton M, Johnson PW, Martin WM, Rankin EM, James LE, Gregory WM, Qian W, Lee SM; London Lung Cancer Group. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol. 2005 Jan 1;23(1):142-53. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# BTOG1: Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. link to original article EuroPMC
==MVP (Vinblastine)==
MVP: Mitomycin, Vinblastine, Platinol (Cisplatin)
===Regimen variant #1===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Danson et al. 2003	1997-2001 	Phase 3 (C)	GC 	Did not meet primary endpoint of OS
====Chemotherapy====
*Mitomycin (Mutamycin) as follows:
**Cycles 1, 2, 4: 8 mg/m2 IV bolus once on day 1
*Vinblastine (Velban) 6 mg/m2 (maximum dose of 10 mg) IV bolus once on day 1
*Cisplatin (Platinol) 50 mg/m2 IV once on day 1
21-day cycle for 4 cycles
===Regimen variant #2===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Ruckdeschel et al. 1986 (ECOG E1581)	1981-1983 	Phase 3 (E-de-esc)	1. CAMP2. EC 3. VC 	Did not meet primary endpoint
Bonomi et al. 1989 (ECOG E1583) 	1984-01 to 1985-07 	Phase 3 (C) 	1. VP2. MVP/CAMP 3. Carboplatin 4. Iproplatin	Might have shorter OS
Veeder et al. 1992 	Not reported 	Phase 3 (C) 	Mitomycin 	Might have longer OS
Smith et al. 2001 	1995-1998 	Phase 3 (C) 	MVP x 3 	Did not meet co-primary endpoint of OS
Booton et al. 2006 (BTOG1) 	2001-06 to 2002-11 	Phase 3 (C) 	DCb 	Did not meet primary endpoint of OS12OS12: 35% vs 39%
====Chemotherapy====
*Mitomycin (Mutamycin) 10 mg/m2 IV over 5 to 15 minutes once on day 1
*Vinblastine (Velban) 6 mg/m2 IV push once on day 1
*Cisplatin (Platinol) 60 mg/m2 IV over 2 hours once on day 1
28-day cycles
===References===
# ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22. link to original article EuroPMC
# ECOG E1583: Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1989 Nov;7(11):1602-13. link to original article EuroPMC
# Veeder MH, Jett JR, Su JQ, Mailliard JA, Foley JF, Dalton RJ, Etzell PS, Marschke RF Jr, Kardinal CG, Maksymiuk AW, Ebbert LP, Tazelaar HD, Witrak GA. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992 Nov 1;70(9):2281-7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001 Mar 1;19(5):1336-43. link to original article EuroPMC
# Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2003 Aug 1;98(3):542-53. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# BTOG1: Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006 Jul;17(7):1111-9. Epub 2006 Apr 7. link to original article EuroPMC
==MVP (Vindesine)==
MVP: Mitomycin, Vindesine, Platinol (Cisplatin)
PVM: Platinol (Cisplatin), Vindesine, Mitomycin
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
González Barón et al. 1994	1989-1992 	Phase 3 (E-switch-ic)	MIP 	Did not meet primary endpoint of ORR
Gridelli et al. 1996 	1990-1994 	Phase 3 (C) 	MEV 	Did not meet primary endpoint of ORR
Jelić et al. 2001 	1990-1996 	Phase 3 (C) 	MVC 	Shorter OS
Boni et al. 1998 	1992-1996 	Phase 3 (C) 	MVP; CI 	Did not meet endpoint of OS
====Chemotherapy====
*Mitomycin (Mutamycin) as follows:
**Cycles 1, 2, 4, 6: 8 mg/m2 IV bolus once on day 1
*Vindesine (Eldisine) as follows:
**Cycle 1: 3 mg/m2 IV bolus once per day on days 1, 8, 15, 22
**Cycles 2 to 6: 3 mg/m2 IV bolus once per day on days 1 & 15
*Cisplatin (Platinol) 125 mg/m2 IV once on day 1
28-day cycle for up to 6 cycles
===References===
# González Barón M, Feliu J, Espinosa E, García Girón C, Blanco E, Garrido P, Colmenarejo A, Ordóñez A, Moyano A, de la Gándara I, Zamora P; ONCOPAZ Cooperative Group. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. Ann Oncol. 1994 Apr;5(4):323-7. link to original article EuroPMC
# Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR; GOSCI. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. Ann Oncol. 1996 Oct;7(8):821-6. link to original article EuroPMC
# Boni C, Savoldi L, Bisagni G, Ceci G, Crinò L, De Lisi V, Di Costanzo F, Lasagni L, Manenti AL, Moretti G, Rondini E, Sassi M, Zadro A; GOIRC. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC). Eur J Cancer. 1998 Nov;34(12):1974-6. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Jelić S, Mitrović L, Radosavljević D, Elezar E, Babović N, Kovcin V, Tomasević Z, Kovacević S, Gavrilović D, Radulović S. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer. 2001 Oct;34(1):1-13. link to original article EuroPMC
==Paclitaxel monotherapy==
===Regimen variant #1, 100 mg/m2, 3 out of 4 weeks===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Comella et al. 2004 (SICOG 9909)	1999-2003 	Phase 3 (E-de-esc)	1. Gemcitabine	Not reported
Comella et al. 2004 (SICOG 9909)	1999-2003 	Phase 3 (E-de-esc)	2. GT 3. GV 	Seems to have shorter OS (primary endpoint)
====Chemotherapy====
*Paclitaxel (Taxol) 100 mg/m2 IV once per day on days 1, 8, 15
28-day cycle for up to 6 cycles
===Regimen variant #2, 200 mg/m2 q3wk===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Ranson et al. 2000	1995-1997 	Phase 3 (E-esc)	Best supportive care	Seems to have longer OS (primary endpoint)Median OS: 6.8 vs 4.8 mo(HR 0.68, 95% CI 0.49-0.996)
====Chemotherapy====
*Paclitaxel (Taxol) 200 mg/m2 IV over 3 hours once on day 1
21-day cycles
===Regimen variant #3, 225 mg/m2 q3wk===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Lilenbaum et al. 2005 (CALGB 9730)	1997-2000 	Phase 3 (C)	CP 	Did not meet primary endpoint of OSMedian OS: 6.7 vs 8.8 mo(HR 1.10, 95% CI 0.85-1.30)
====Chemotherapy====
*Paclitaxel (Taxol) 225 mg/m2 IV over 3 hours once on day 1
21-day cycle for 6 cycles
===References===
# Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000 Jul 5;92(13):1074-80. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# SICOG 9909: Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G, Maiorino L, Guida M, Panza N, Mancarella S, Cioffi R. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer. 2004 Aug 2;91(3):489-97. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC
#CALGB 9730: Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol. 2005 Jan 1;23(1):190-6. link to original articledosing details in manuscript have been reviewed by our editors EuroPMC NCT00003117
==Vindesine monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Einhorn et al. 1986	1982-1984 	Phase 3 (C)	1. Cisplatin & Vindesine2. MVP	Did not meet endpoint of OS
Furuse et al. 1996 	1991-1993 	Phase 3 (C)	Vinorelbine 	Lower ORR
====Chemotherapy====
*Vindesine (Eldisine) as follows:
**Cycle 1: 3 mg/m2 IV once per day on days 1, 8, 15, 22
**Cycle 2 onwards: 3 mg/m2 IV once per day on days 1 & 15
28-day cycles
===References===
# Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, Stephens D, Hui S. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol. 1986 Jul;4(7):1037-43. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# Furuse K, Fukuoka M, Kuba M, Yamori S, Nakai Y, Negoro S, Katagami N, Takada Y, Kinuwaki E, Kawahara M, Kubota K, Sakuma A, Niitani H; Japan Vinorelbine Lung Cancer Cooperative Study Group. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). Ann Oncol. 1996 Oct;7(8):815-20. link to original article EuroPMC
==Vinorelbine monotherapy==
===Regimen variant #1, 25 mg/m2/week===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Furuse et al. 1996	1991-1993 	Phase 3 (E-switch-ic)	Vindesine 	Higher ORR
====Chemotherapy====
*Vinorelbine (Navelbine) 25 mg/m2 IV once on day 1
7-day cycles
===Regimen variant #2, 30 mg/m2/week===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Depierre et al. 1994 	1989-1991 	Phase 3 (C) 	CVb 	Shorter TTP
Le Chevalier et al. 1994	1989-1991 	Phase 3 (E-de-esc) 	1. Cisplatin & Vindesine	Not reported
Le Chevalier et al. 1994	1989-1991 	Phase 3 (E-de-esc) 	2. CVb 	Shorter OS
Crawford et al. 1996 	1990-1992 	Randomized (E-RT-switch-ic)	FULV 	Seems to have longer OS
====Chemotherapy====
*Vinorelbine (Navelbine) 30 mg/m2 IV once on day 1
7-day cycles
===Regimen variant #3, 30 mg/m2, 2 out of 3 weeks===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Frasci et al. 2001	Not reported 	Phase 3 (C)	Gemcitabine & Vinorelbine	Shorter OS
Note: To our knowledge, this regimen variant was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
====Chemotherapy====
*Vinorelbine (Navelbine) 30 mg/m2 IV once per day on days 1 & 8
21-day cycles
===References===
#Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal-Celigny P, Badri N, Besenval M. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol. 1994 Jan;5(1):37-42. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffle P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360-7. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Crawford J, O'Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 1996 Oct;14(10):2774-84. Erratum in: J Clin Oncol 1996 Dec;14(12):3175. Spiridonitis CH [corrected to Spiridonidis CH]. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
# Furuse K, Fukuoka M, Kuba M, Yamori S, Nakai Y, Negoro S, Katagami N, Takada Y, Kinuwaki E, Kawahara M, Kubota K, Sakuma A, Niitani H; Japan Vinorelbine Lung Cancer Cooperative Study Group. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). Ann Oncol. 1996 Oct;7(8):815-20. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
#Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, DeCataldis G, Belli M, Iannelli N, Massidda B, Mascia V, Comella G, De Lena M; Southern Italy Cooperative Oncology Group. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer: a Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer. 2001 Dec;34 Suppl 4:S65-9. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
==VeIP==
VeIP: Velban (Vinblastine), Ifosfamide, Platinol (Cisplatin)
VIP: Vinblastine, Ifosfamide, Platinol (Cisplatin)
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Kosmidis et al. 1996a	1992-1994 	Phase 3 (C)	VIP-16 	Did not meet primary endpoint of ORR
====Chemotherapy====
*Vinblastine (Velban) 6 mg/m2 IV once on day 1
*Ifosfamide (Ifex) 3000 mg/m2 IV once on day 1
*Cisplatin (Platinol) 100 mg/m2 IV once on day 1
21-day cycles
===References===
# Kosmidis P, Mylonakis N, Fountzilas G, Pavlidis N, Samantas E, Karabelis A, Kattis K, Skarlos D; HeCOG. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Ann Oncol. 1996 Jul;7(5):517-20. link to original article dosing details in abstract have been reviewed by our editors EuroPMC
=Maintenance after first-line therapy=
==Erlotinib monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Cappuzzo et al. 2010 (SATURN) 	2005-2008 	Phase 3 (E-RT-esc) 	Placebo 	Longer PFS (co-primary endpoint)Median PFS: 12.3 vs 11.1 weeks(HR 0.71, 95% CI 0.62-0.82)
Pérol et al. 2012 (IFCT-GFPC 0502)	2006-2009 	Phase 3 (E-esc) 	1. Gemcitabine	Not reported
Pérol et al. 2012 (IFCT-GFPC 0502)	2006-2009 	Phase 3 (E-esc) 	2. Observation	Longer PFS (primary endpoint)Median PFS: 2.9 vs 1.9 mo(HR 0.69, 95% CI 0.54-0.88)
Cicènas et al. 2016 (IUNO) 	2011-2014 	Phase 3 (E-RT-switch-ic)	See link 	See link
Note: while SATURN was technically a positive study for erlotinib, the median PFS gain was 1.2 weeks. This study was the basis of an FDA approval in 2010, which was later revised after the results of IUNO became available. The trials included here did not require EGFR mutation as a condition for enrollment.
====Preceding treatment====
*SATURN and IUNO: First-line platinum-doublet therapy x 4
*IFCT-GFPC 0502: First-line GC x 4
====Targeted therapy====
*Erlotinib (Tarceva) 150 mg PO once per day on days 1 to 28
28-day cycles
===References===
# SATURN: Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. Epub 2010 May 20. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00556712
# IFCT-GFPC 0502: Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00300586
# IUNO: Cicènas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 2016 Dec;102:30-37. Epub 2016 Oct 20. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01328951
==Gefitinib monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Gaafar et al. 2011 (EORTC 08021)	2004-2009 	Phase 3 (E-esc)	Placebo 	Did not meet primary endpoint of OSMedian OS: 10.9 vs 9.4 mo(HR 0.83, 95% CI 0.60-1.15)
Zhang et al. 2012 (INFORM) 	2008-09-28 to 2009-08-11	Phase 3 (E-esc)	Placebo 	Longer PFS (primary endpoint)Median PFS: 4.8 vs 2.6 mo(HR 0.42, 95% CI 0.33-0.55)
====Preceding treatment====
*First-line platinum-doublet therapy x 4
====Targeted therapy====
*Gefitinib (Iressa) 250 mg PO once per day
Continued indefinitely
===References===
# EORTC 08021: Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP; EORTC Lung Cancer Group; Italian Lung Cancer Project. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer. 2011 Oct;47(15):2331-40. Epub 2011 Jul 28. link to original article https://doi.org/10.1016/j.ejca.2011.06.045 EuroPMC NCT00091156
# INFORM: Zhang L, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Zhang X, Hayashi N, Wang M; INFORM investigators. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012 May;13(5):466-75. Epub 2012 Apr 17. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00770588
## Update: Zhao H, Fan Y, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Wang M, Zhang L; INFORM investigators. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol. 2015 Apr;10(4):655-64. link to original article EuroPMC
==Sunitinib monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Baggstrom et al. 2017 (CALGB 30607)	2008-2013 	Phase 3 (E-esc)	Placebo 	Longer PFS (primary endpoint)Median PFS: 4.3 vs 2.6 mo(HR 0.62, 95% CI 0.47-0.82)
====Preceding treatment====
*CALGB 30607: First-line platinum-doublet therapy x 4, with or without bevacizumab
====Targeted therapy====
*Sunitinib (Sutent) 37.5 mg PO once per day
Continued indefinitely
===References===
# CALGB 30607: Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, Baker S Jr, Feliciano J, Novotny P, Hahn O, Crawford JA, Vokes EE. Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance). J Thorac Oncol. 2017 May;12(5):843-849. Epub 2017 Feb 1. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00693992
=Advanced or metastatic disease, subsequent lines of therapy=
==Erlotinib monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator 	Comparative Efficacy
Shepherd et al. 2005 (NCIC-CTG BR.21)	2001-2003 	Phase 3 (E-RT-esc) 	Placebo 	Longer OS (primary endpoint)Median OS: 6.7 vs 4.7 mo(aHR 0.70, 95% CI 0.58-0.85)
Herbst et al. 2011 (BeTa) 	2005-2008 	Phase 3 (C) 	Erlotinib & Bevacizumab 	Did not meet primary endpoint of OSMedian OS: 9.2 vs 9.3 mo(HR 1.03, 95% CI 0.85-1.25)
Natale et al. 2011 (ZEST) 	2006-10 to 2007-11 	Phase 3 (C) 	Vandetanib 	Did not meet primary endpoint of PFS
Ciuleanu et al. 2012 (TITAN) 	2006-2010 	Phase 3 (E-switch-ooc)	Investigator's choice of:1a. Docetaxel1b. Pemetrexed 	Did not meet primary endpoint of OS
Karampeazis et al. 2013 (CT/06.05) 	2006-2010 	Phase 3 (E-switch-ooc)	Pemetrexed 	Did not meet primary endpoint of TTP
Scagliotti et al. 2012 (SUN 1087) 	2007-2009 	Phase 3 (C) 	Erlotinib & Sunitinib 	Did not meet primary endpoint of OS
Garassino et al. 2013 (TAILORNSCLC) 	2007-2012 	Phase 3 (E-switch-ooc)	Docetaxel 	Seems to have shorter OS (primary endpoint)Median OS: 5.4 vs 8.2 mo(aHR 1.37, 95% CI 1.00-1.89)
Ramalingam et al. 2012 (A7471028) 	2008-2009 	Randomized Phase 2 (C)	Dacomitinib 	Seems to have shorter PFS
Scagliotti et al. 2015 (ADVIGO 1018) 	2008-2010 	Phase 3 (C) 	Erlotinib & Figitumumab 	Did not meet primary endpoint of OS
Kawaguchi et al. 2014 (DELTANSCLC) 	2009-2012 	Phase 3 (E-switch-ooc)	Docetaxel 	Might have shorter PFS (primary endpoint)
Urata et al. 2016 (WJOG 5108L) 	2009-2012 	Phase 3 (C) 	Gefitinib 	Inconclusive whether non-inferior PFS
Smit et al. 2016 (CurrentS) 	2010 to not reported	Phase 3 (C) 	Erlotinib; high-dose 	Did not meet primary endpoint of PFS
Wang et al. 2017a 	2010-2014 	Phase 3 (C) 	Erlotinib, Bevacizumab, Panitumumab 	Seems to have shorter OS
Scagliotti et al. 2015 (MARQUEE) 	2011-01 to 2012-07 	Phase 3 (C) 	Erlotinib & Tivantinib 	Did not meet primary endpoint of OS
Yoshioka et al. 2015 (ATTENTION) 	2011-08 to 2012-10 	Phase 3 (C) 	Erlotinib & Tivantinib 	Did not meet primary endpoint of OS
Ramalingam et al. 2014 (ARCHER 1009) 	2011-2013 	Phase 3 (C) 	Dacomitinib 	Did not meet primary endpoint of PFS
Cicènas et al. 2016 (IUNO) 	2011-2014 	Phase 3 (E-switch-ic) 	See link 	See link
Gridelli et al. 2018 (AvaALL) 	2011-2015 	Phase 3 (C) 	Investigator's choice of:1a. Docetaxel & Bevacizumab1b. Erlotinib & Bevacizumab1c. Pemetrexed & Bevacizumab	Might have shorter OSMedian OS: 10.2 vs 11.9 mo(HR 1.19, 90% CI 1.00-1.41)
Spigel et al. 2016 (METLung) 	2012-01 to 2013-08 	Phase 3 (C) 	Erlotinib & Onartuzumab 	Might have longer OS
Soria et al. 2015 (LUX-Lung 8) 	2012-2014 	Phase 3 (C) 	Afatinib 	Seems to have shorter OS1
Neal et al. 2016 (ECOG-ACRIN 1512) 	2013-2014 	Randomized Phase 2 (C)	1. Cabozantinib 	Shorter PFS
Neal et al. 2016 (ECOG-ACRIN 1512) 	2013-2014 	Randomized Phase 2 (C)	2. Cabozantinib & Erlotinib 	Shorter PFS
Goldman et al. 2020 (JUNIPER) 	2014-2017 	Phase 3 (C) 	Abemaciclib 	Did not meet primary endpoint of OS
1Reported efficacy is based on the 2021 update.
Note: the trials included here did not require EGFR mutation as a condition for enrollment. Given the FDA limitation on use in this setting issued in 2016, these regimens have been moved to the historical page. Note that there is another trial named TAILOR in colorectal cancer and another trial named DELTA in indolent lymphoma.
====Biomarker eligibility criteria====
*JUNIPER: KRAS G12 or G13 mutation
====Targeted therapy====
*Erlotinib (Tarceva) 150 mg PO once per day on days 1 to 28
28-day cycles
===References===
# NCIC-CTG BR.21: Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00036647
# ZEST: Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011 Mar 10;29(8):1059-66. Epub 2011 Jan 31. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00364351
## Dataset: Project Data Sphere
# BeTa: Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54. link to original article link to PMC article dosing details in abstract have been reviewed by our editors EuroPMC NCT00130728
# TITAN: Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012 Mar;13(3):300-8. Epub 2012 Jan 24. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00556322
# SUN 1087: Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, Wierzbicki RF, Albert I, Thomas M, Miziara JE, Papai ZS, Karaseva N, Thongprasert S, Portulas ED, von Pawel J, Zhang K, Selaru P, Tye L, Chao RC, Govindan R. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2070-8. Epub 2012 May 7. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT00457392
# A7471028: Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20;30(27):3337-44. Epub 2012 Jul 2. link to original article link to PMC article EuroPMC NCT00769067
# CT/06.05: Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013 Aug 1;119(15):2754-64. Epub 2013 May 9. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00440414
# TAILORNSCLC: Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep;14(10):981-8. Epub 2013 Jul 22. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00637910
# DELTANSCLC: Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014 Jun 20;32(18):1902-8. Epub 2014 May 19. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC
# ARCHER 1009: Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. Epub 2014 Oct 15.link to original article EuroPMC NCT01360554
# ADVIGO 1018: Scagliotti GV, Bondarenko I, Blackhall F, Barlesi F, Hsia TC, Jassem J, Milanowski J, Popat S, Sanchez-Torres JM, Novello S, Benner RJ, Green S, Molpus K, Soria JC, Shepherd FA. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol. 2015 Mar;26(3):497-504. Epub 2014 Nov 13. link to original article EuroPMC NCT00673049
# LUX-Lung 8: Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907. Epub 2015 Jul 5. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01523587
##PRO analysis: Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clin Lung Cancer. 2018 Jan;19(1):74-83.e11. Epub 2017 Jun 23. link to original article EuroPMC
##Update: Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Isla D, Morabito A, Min YJ, Ardizzoni A, Bender S, Cseh A, Felip E. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine. 2021 Jun 18;37:100940. link to original article link to PMC article EuroPMC
# ATTENTION: Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, Ahn MJ, Hirashima T, Maemondo M, Kim SW, Kurosaki M, Akinaga S, Park K, Tsai CM, Tamura T, Mitsudomi T, Nakagawa K. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol. 2015 Oct;26(10):2066-72. Epub 2015 Jul 7. link to original article EuroPMC NCT01377376
# MARQUEE: Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Aug 20;33(24):2667-74. Epub 2015 Jul 13. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01244191
# WJOG 5108L: Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol. 2016 Sep 20;34(27):3248-57. Epub 2016 Mar 28. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC UMIN000002014
# CurrentS: Smit EF, Wu YL, Gervais R, Zhou C, Felip E, Feng J, Guclu SZ, Hoiczyk M, Dorokhova E, Freudensprung U, Grange S, Perez-Moreno PD, Mitchell L, Reck M. A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). Lung Cancer. 2016 Sep;99:94-101. Epub 2016 Jun 27. link to original article EuroPMC NCT01183858
# IUNO: Cicènas S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, Mudie N, Wu YL. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Lung Cancer. 2016 Dec;102:30-37. Epub 2016 Oct 20. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01328951
# ECOG-ACRIN 1512: Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS; ECOG-ACRIN. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1661-1671. Epub 2016 Nov 4. link to original article dosing details in abstract have been reviewed by our editors link to PMC article EuroPMC NCT01708954
# METLung: Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J Clin Oncol. 2017 Feb;35(4):412-420. Epub 2016 Dec 12. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT01456325
# Wang Y, Wang H, Jiang Y, Zhang Y, Wang X. A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer. Biomed Pharmacother. 2017 May;89:875-879. Epub 2017 Mar 6. link to original article EuroPMC
# AvaALL: Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):e183486. Epub 2018 Dec 13. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792. link to original article link to PMC article dosing details in supplement have been reviewed by our editors EuroPMC NCT01351415
# JUNIPER: Goldman JW, Mazieres J, Barlesi F, Dragnev KH, Koczywas M, Göskel T, Cortot AB, Girard N, Wesseler C, Bischoff H, Nadal E, Park K, Lu S, Taus A, Cobo M, Estrem ST, Wijayawardana SR, Turner K, Oakley GJ 3rd, Hurt KC, Chiang AY, Hossain AM, John WJ, Paz-Ares L. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. Front Oncol. 2020 Oct 26;10:578756. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT02152631
#WJOG5108LFS: Katakami N, Yokoyama T, Morita S, Okamoto T, Urata Y, Hattori Y, Iwamoto Y, Sato Y, Ikeda N, Takahashi T, Daga H, Oguri T, Fujisaka Y, Nishino K, Sugawara S, Kozuki T, Oki M, Yamamoto N, Nakagawa K. Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS). Int J Clin Oncol. 2023 Jan;28(1):79-88. Epub 2022 Nov 21. link to original article EuroPMC UMIN000002014
Category:Non-small cell lung cancer regimens
Category:Historical regimens
Category:Disease-specific pages
Category:Lung cancers